Tenofovir: A new option for the treatment of chronic hepatitis B
作者： Walid Ayoub
DOI: 10.2147/VAAT.S4712
关键词:
摘要: Treatment of chronic hepatitis B (CHB) continues to evolve. Over the last decade, progressively lower levels serum HBV DNA have been used as a threshold for treatment. A high degree antiviral potency and low rate resistance are two most important factors in choice an agent therapy CHB. Achieving rapid viral suppression is also key factor choosing first line therapy. Swift potent decreases risk hepatic decompensation, development hepatocellular carcinoma subsequent need liver transplantation. Currently, entecavir tenofovir nucleoside nucleotide analogs with lowest treatment-naive patients. This review will evaluate safety efficacy use disoproxil fumarate, newest agent, treatment patients
paperity.org参考文章(41)
Xiaoping Qi, Shelly Xiong, Huiling Yang, Michael Miller, William E Delaney IV, None, In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antiviral Therapy. ,vol. 12, pp. 355- 362 ,(2007)
Joel E Gallant, Paul E Klotman, Paul E Sax, Renal safety of tenofovir disoproxil fumarate. Aids Reader. ,vol. 17, pp. 90- ,(2007)
Karine Lacombe, Joël Gozlan, Pierre-Yves Boelle, Lawrence Serfaty, Fabien Zoulim, Alain-Jacques Valleron, Pierre-Marie Girard, Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS. ,vol. 19, pp. 907- 915 ,(2005) , 10.1097/01.AIDS.0000171404.07995.5C
D. Amarapurkar, 901 EFFICACY OF COMBINATION OF ENTECAVIR AND TENOFOVIR TREATMENT IN HEPATITIS B RELATED DECOMPENSATED CHRONIC LIVER DISEASE: PILOT STUDY Journal of Hepatology. ,vol. 50, ,(2009) , 10.1016/S0168-8278(09)60903-X
T. Berg, B. Moller, H. Trinh, S. Chan, P. Marcellin, E. Suarez, A. Snow-Lampart, D. Oldach, J. Sorbel, K. Borroto-Esoda, D. Frederick, F. Rousseau, 903 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF (FTC/TDF) FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN PATIENTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL Journal of Hepatology. ,vol. 50, ,(2009) , 10.1016/S0168-8278(09)60905-3
Florian van Bömmel, Bernhard Zöllner, Christoph Sarrazin, Ulrich Spengler, Dietrich Hüppe, Bernd Möller, Heinz-Hubert Feucht, Bertram Wiedenmann, Thomas Berg, Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. ,vol. 44, pp. 318- 325 ,(2006) , 10.1002/HEP.21253
Florian van Bömmel, Thomas Berg, Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology. ,vol. 42, pp. 239- 240 ,(2005) , 10.1002/HEP.20765
W. S. AYOUB, E. B. KEEFFE, Review article: current antiviral therapy of chronic hepatitis B. Alimentary Pharmacology & Therapeutics. ,vol. 28, pp. 167- 177 ,(2008) , 10.1111/J.1365-2036.2008.03731.X
A. Erhardt, D. Hüppe, M. Bourlière, C. Sarrazin, J. Trojan, P. Buggisch, J. Petersen, U. Spengler, S. Brost, M. Schuchmann, H. Wasmuth, J. Reijnders, K. Deterding, K. Rutter, B. Fülöp, H.-H. Feucht, B. Wiedenmann, T. Berg, F. van Bömmel, R. deMan, P. Ferenci, J.P. Bronowiki, H. Wedemeyer, 929 EVALUATION OF SAFETY AND TOLERABILITY OF TENOFOVIR DF (TDF) LONG TERM MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE EXPERIENCED PATIENTS WITH HBV MONOINFECTION Journal of Hepatology. ,vol. 50, ,(2009) , 10.1016/S0168-8278(09)60931-4
F. van B¨ommel, R.A. de Man, K. Stein, D. Hüuppe, J. Petersen, P. Buggisch, H. Wedemeyer, C. Sarrazin, J. Trojan, W. B¨ocher, A. Erhardt, U. Spengler, J.G. Reijnders, H.E. Wasmuth, H.H. Feucht, B. Wiedenmann, T. Berg, 73 A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV-MONOINFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOG EXPERIENCE Journal of Hepatology. ,vol. 48, pp. S32- ,(2008) , 10.1016/S0168-8278(08)60075-6